Dare Bioscience DARE Institutional Ownership

Updated Oct 10, 2026

Dare Bioscience, Inc. (NASDAQ:DARE) counted 27 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• These investors held 8.58% of Dare Bioscience's outstanding shares at the end of Q2 2026, up from 7.04% in Q1 2026.
• Total shares held in Dare Bioscience rose 27.02% versus Q1 2026, while the number of holders rose 22.73% versus Q2 2025.
• Of these 27 holders, 18 added to their positions, 4 reduced their stakes and 5 left their positions unchanged.
• The aggregate institutional position in Dare Bioscience was 1.3Mn shares at the end of Q2 2026, up 276.93K from the prior quarter and up 397.43K from a year earlier.
• Vanguard Capital Management LLC held the largest position in DARE at 640.88K shares as of June 30, 2026, or 4.22% of shares outstanding.
• Holders that added the most shares of Dare Bioscience in Q2 2026 were Vanguard Capital Management LLC (+178.57K shares), BlackRock, Inc. (+47.28K shares), Us Bancorp De (+29.55K shares), Vanguard Fiduciary Trust Co (+25.33K shares) and State Street Corp (+23.9K shares).
• The biggest cuts to DARE positions during Q2 2026 came from Geode Capital Management, LLC (-37.75K shares), UBS Group AG (-36.55K shares), Raymond James Financial Inc (-470 shares) and Mather Group, LLC (-1 share).
• Per Business Quant data, the 10 largest holders of Dare Bioscience at the end of Q2 2026 were Vanguard Capital Management LLC (640.88K shares), Geode Capital Management, LLC (140.09K shares), Us Bancorp De (120.92K shares), Vanguard Fiduciary Trust Co (91.27K shares), BlackRock, Inc. (64.25K shares), State Street Corp (47.41K shares), Jane Street Group, LLC (36.09K shares), Northern Trust Corp (34.21K shares), HRT Financial LP (22.43K shares) and Virtu Financial LLC (15.8K shares).